A Repeated Dose-finding Study of Sarilumab in Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (SKYPS)

Trial Identifier: DRI13926
Sponsor: Sanofi
Collaborator:
Regeneron Pharmaceuticals
Start Date: August 2018
Primary Completion Date: March 2028
Study Completion Date: January 2031
Condition: Muscle, Bone & Joint - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
ARGENTINA, Buenos Aires Buenos Aires, ARGENTINA, 1023
ARGENTINA, Tucumán San Miguel De Tucumán, Tucumán, ARGENTINA, T4000
CANADA, Alberta Calgary, Alberta, CANADA, T3B 6A9
FINLAND Helsinki, FINLAND, 00029
FRANCE Bron, FRANCE, 69500
FRANCE Montpellier, FRANCE, 34295
FRANCE Paris, FRANCE, 75015
GERMANY Berlin, GERMANY, 13353
GERMANY Berlin, GERMANY, 13125
GERMANY Hamburg, GERMANY, 22081
GERMANY Sankt Augustin, GERMANY, 53757
GERMANY Sendenhorst, GERMANY, 48324
GREECE Athens, GREECE, 115 27
GREECE Thessaloniki, GREECE, 546 42
IRELAND, Dublin Crumlin, Dublin, IRELAND, D12 N512
ITALY, Genova Genoa, Genova, ITALY, 16147
ITALY, Milano Milan, Milano, ITALY, 20122
ITALY, Roma Rome, Roma, ITALY, 00165
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 119991
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 117997
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 115522
RUSSIAN FEDERATION Ufa, RUSSIAN FEDERATION, 450083
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08035
SPAIN, Barcelona [Barcelona] Esplugues De Llobregat, Barcelona [Barcelona], SPAIN, 08950
SPAIN, Madrid Madrid, SPAIN, 28009
SPAIN, Madrid Madrid, SPAIN, 28010
SPAIN, Málaga Málaga, SPAIN, 29010
SPAIN, Valencia Valencia, SPAIN, 46026
UNITED KINGDOM, Leeds Leeds, UNITED KINGDOM, LS1 3EX
UNITED KINGDOM, Liverpool Liverpool, UNITED KINGDOM, L12 2AP
UNITED KINGDOM, London, City of London, London, City of, UNITED KINGDOM, WC1N 3JH